Full video transcriptClick to expand
Auto-generated transcript of @joysparkleshine's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00The Battle of the Ozempic Oskars ED's is still going on,
- 0:03and this one's come under a tawness group name.
- 0:06Not only does it look like she's had obvious work done
- 0:08to her face, but a lot of people don't like
- 0:11that have changed her face.
- 0:12She looks way too thin, but last minute,
- 0:15there were stylists scrambling
- 0:16because they wanted to make sure their clients
- 0:18weren't going out looking too thin,
- 0:21and they added things on her shoulders
- 0:23so her shoulders didn't seem too bony.
- 0:25This one people were concerned about
- 0:27because her body is so small
- 0:29that her head looks too big for it,
- 0:31and looks like it could fall off.
- 0:32We got Maad Apatow, who was a beautiful girl,
- 0:35but again, looks like she's way too thin on Ozempic,
- 0:38and nobody knows what's going on.
- 0:40You can see the collarbones, the shoulders,
- 0:42her arms look really, really thin.
- 0:44He had Demi Moore, who allegedly had last minute changes
- 0:47to what she was wearing, and she is now quoted as saying,
- 0:49I'm never gonna show my back ever because of what's happened.
- 0:52These women were already so beautiful,
- 0:54it makes me so sad they don't need to fill their bodies
- 0:56full of poisons or with their actions,
- 0:58try to influence us and tell us this is what we should.
Do celebrities actually use Ozempic? Separating Oscar rumors from GLP-1 facts
Quick answer
GLP-1 receptor agonists like semaglutide produce statistically significant weight loss, with clinical trials showing up to 15% body weight reduction, but roughly a quarter to a third of that loss can come from lean muscle mass rather than fat tissue, particularly without structured resistance training. Visible signs of rapid weight loss, including prominent collarbones and reduced muscle bulk, are documented side effects in real patients but cannot be used to diagnose drug use or eating disorders from a photograph or video. Attributing celebrity body changes to Ozempic without disclosure or clinical confirmation is speculation, not health journalism.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Do celebrities actually use Ozempic? Separating Oscar rumors from GLP-1 facts, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Do celebrities actually use Ozempic? Separating Oscar rumors from GLP-1 facts" from Joy. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide produce statistically significant weight loss, with clinical trials showing up to 15% body weight reduction, but roughly a quarter to a third of that loss can come from lean muscle mass rather than fat tissue, particularly without structured resistance training.
The reason this review is not generic is the source wording and the canonical claim label "glp1 the battle of the oscar ozempic eds demi moore emma stone ma." In this clip, the useful excerpt is: "The Battle of the Ozempic Oskars ED's is still going on, and this one's come under a tawness group name." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists like semaglutide produce statistically significant weight loss, with clinical trials showing up to 15% body weight reduction, but roughly a quarter to a third of that loss can come from lean muscle mass rather than fat tissue, particularly without structured resistance training.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide produce statistically significant weight loss, with clinical trials showing up to 15% body weight reduction, but roughly a quarter to a third of that loss can come from lean muscle mass rather than fat tissue, particularly without structured resistance training. Visible signs of rapid weight loss, including prominent collarbones and reduced muscle bulk, are documented side effects in real patients but cannot be used to diagnose drug use or eating disorders from a photograph or video. Attributing celebrity body changes to Ozempic without disclosure or clinical confirmation is speculation, not health journalism.
- No named celebrity in this video has publicly confirmed using semaglutide or any GLP-1 drug. Attribution of their appearance to Ozempic is speculation with no disclosed sourcing.
- Wilding et al. (2021, NEJM) found semaglutide users lost an average 14.9% body weight over 68 weeks, confirming real, significant physical changes in actual patients.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- No named celebrity in this video has publicly confirmed using semaglutide or any GLP-1 drug. Attribution of their appearance to Ozempic is speculation with no disclosed sourcing.
- Wilding et al. (2021, NEJM) found semaglutide users lost an average 14.9% body weight over 68 weeks, confirming real, significant physical changes in actual patients.
- Daly et al. (2022, Obesity) found 25-39% of weight lost on GLP-1 therapy without resistance training comes from lean muscle mass, which can produce a visibly gaunt or bony appearance.
- Semaglutide is FDA-approved for chronic weight management (Wegovy, 2021) and type 2 diabetes (Ozempic, 2017). Calling it a 'poison' contradicts its established regulatory and clinical record.
- Rodgers et al. (2020, International Journal of Eating Disorders) found social media content linking celebrity thinness to drug use increases disordered eating cognitions in adolescent and young adult viewers.
- Visible thinness, prominent collarbones, or low body weight cannot be used to diagnose eating disorders or confirm drug use from appearance alone. These are not clinical diagnostic criteria.
- If you have concerns about weight, GLP-1 medications, or disordered eating patterns, a board-certified clinician or registered dietitian is the appropriate first contact, not social media commentary.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @joysparkleshine actually say?
The creator looked at several women on the 2026 Oscar red carpet and argued, essentially, that GLP-1 drugs like Ozempic are making Hollywood dangerously thin. She said one celebrity's "body is so small that her head looks too big for it," called the drugs "poisons," and suggested stylists were scrambling last-minute to hide "too bony" shoulders. She also claimed Demi Moore made comments about never showing her back again because of her appearance. The disclaimer at the end of the caption says this is "entertainment" and "no facts" — but nearly a million people watched it, and the framing was presented as genuine concern, not satire.
None of the named celebrities have publicly confirmed using semaglutide or any GLP-1 medication. Attributing their bodies to Ozempic is speculation dressed as observation.
Does the science back this up?
There is real, documented evidence that GLP-1 receptor agonists cause significant weight loss, including muscle loss, which can produce a gaunt appearance. That part is grounded in data. The problem is the leap from "she looks thin" to "she's on Ozempic" to "she has an eating disorder."
A 2021 trial published in the New England Journal of Medicine (Wilding et al.) found that semaglutide produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. A meaningful portion of that loss is lean mass, not just fat. Daly et al. (2022, Obesity) confirmed that without resistance training, roughly 25-39% of weight lost on GLP-1 therapy can come from muscle. So yes, people on these drugs can look thin in ways that concern clinicians. But that is not the same as saying every thin celebrity is on Ozempic, or that thinness at the Oscars is proof of drug use or disordered eating. The creator conflates visible collarbone with clinical pathology, which is not a diagnostic standard anyone uses.
What did they get wrong (or right)?
They got one thing approximately right: clinicians do have legitimate concerns about muscle wasting and a "skinny fat" body composition in patients using GLP-1 drugs without adequate protein intake and exercise. That concern is real and published.
But nearly everything else in the video is either unverifiable or misleading. Calling semaglutide a "poison" is inaccurate. The FDA approved semaglutide for chronic weight management in adults (Wegovy, 2021) and for type 2 diabetes (Ozempic, 2017) based on large randomized controlled trials. The word "poison" implies toxicity without therapeutic window, which is not supported by the safety profile in the literature.
The claim that these celebrities are using Ozempic is pure speculation. The creator offers no sourcing. Linking visible thinness to eating disorders in named individuals without any clinical basis is irresponsible, even under an "entertainment" disclaimer. Naming Maude Apatow and others while implying eating disorder behavior based on appearance alone is the kind of content that researchers say reinforces harmful body image comparisons. Rodgers et al. (2020, International Journal of Eating Disorders) found that social media content linking thinness to celebrity drug use increases disordered eating cognitions in adolescent viewers.
What should you actually know?
GLP-1 drugs produce real, significant weight loss. They also carry real risks that are worth discussing seriously, not spectacularly. Muscle loss, nausea, pancreatitis risk, and potential thyroid concerns are all documented in peer-reviewed literature and listed in FDA labeling. Those are conversations worth having.
What is not worth having is a nearly million-view video that diagnoses celebrities with eating disorders by looking at their collarbones on a red carpet. The creator says she's sad these women "fill their bodies full of poisons" — but the video itself does something arguably more harmful. It packages appearance-based speculation as health concern, gives it a medical-sounding label (Ozempic, ED), and sends it to a predominantly young female audience. A 2023 study by Rodgers and Melioli in Body Image found that exposure to celebrity weight-loss content is associated with increased body dissatisfaction in women aged 18-35, regardless of whether the content is framed as concern or criticism. The framing of sympathy does not neutralize the impact.
If you are genuinely concerned about your own weight, metabolism, or relationship with food, that conversation belongs with a licensed clinician, not a TikTok comment section.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Joy · TikTok creator
961.4K views on this video
The Battle of the Oscar Ozempic EDs Demi Moore Emma Stone Maude Apatow Nicole Kidman Oscars 2026 #oscar #oscars #oscars2026 #emmastone #demimoore This video is all allegedly for entertainment purposes only no facts. This is just commentary questions opinions on trending topics and celebrities. None of what I say in this video is real.
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about no named celebrity in this video has publicly confirmed using?
No named celebrity in this video has publicly confirmed using semaglutide or any GLP-1 drug. Attribution of their appearance to Ozempic is speculation with no disclosed sourcing.
What does the video say about wilding et al. (2021, nejm) found semaglutide users lost an?
Wilding et al. (2021, NEJM) found semaglutide users lost an average 14.9% body weight over 68 weeks, confirming real, significant physical changes in actual patients.
What does the video say about daly et al. (2022, obesity) found 25-39% of weight lost?
Daly et al. (2022, Obesity) found 25-39% of weight lost on GLP-1 therapy without resistance training comes from lean muscle mass, which can produce a visibly gaunt or bony appearance.
What does the video say about semaglutide?
Semaglutide is FDA-approved for chronic weight management (Wegovy, 2021) and type 2 diabetes (Ozempic, 2017). Calling it a 'poison' contradicts its established regulatory and clinical record.
What does the video say about rodgers et al. (2020, international journal of eating disorders) found?
Rodgers et al. (2020, International Journal of Eating Disorders) found social media content linking celebrity thinness to drug use increases disordered eating cognitions in adolescent and young adult viewers.
What does the video say about visible thinness, prominent collarbones,?
Visible thinness, prominent collarbones, or low body weight cannot be used to diagnose eating disorders or confirm drug use from appearance alone. These are not clinical diagnostic criteria.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Joy, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.